Histone Lactylation-mediated PKM2 promotes gemcitabine resistance in pancreatic adenocarcinoma via the AKT/mTOR/SREBP1 Axis.
BACKGROUND Pancreatic adenocarcinoma (PAAD) is a highly malignant tumor. The efficacy of its first-line chemotherapeutic agent, gemcitabine (GEM), is frequently compromised by acquired resistance. Although pyruvate kinase M2 (PKM2) is a potential target for mitigating GEM resistance, the underlying mechanism remains un...